Claims for Patent: 6,426,224

Summary for Patent: 6,426,224

Title:	Oligonucleotide mediated nucleic acid recombination
Abstract:	Methods of recombining nucleic acids, including homologous nucleic acids, are provided. Families of gene shuffling oligonucleotides and their use in recombination procedures, as well as polymerase and ligase mediated recombination methods are also provided.
Inventor(s):	Crameri; Andreas (Reinach, CH), Stemmer; Willem P. C. (Los Gatos, CA), Minshull; Jeremy (Menlo Park, CA), Bass; Steven H. (Hillsborough, CA), Welch; Mark (Fremont, CA), Ness; Jon E. (Sunnyvale, CA), Gustafsson; Claes (Belmont, CA), Patten; Phillip A. (Mountain View, CA)
Assignee:	MaxyGen, Inc. (Redwood City, CA)
Application Number:	09/626,528
Patent Claims:	1. A method of recombining an oligonucleotide set, the method comprising: aligning a plurality of homologous nucleic acid sequences to identify one or more regions of sequence heterogeneity; synthesizing a plurality of different oligonucleotide member types which correspond to one of the regions of heterogeneity; mixing the plurality of different oligonucleotide member types, thereby providing a set of oligonucleotides which comprise a plurality of different oligonucleotide members which comprise the at least one regions of sequence heterogeneity which corresponds to one or more of the regions of heterogeneity in the plurality of homologous nucleic acid sequences; and, recombining one or more member of the oligonucleotide set with one or more nucleic acid corresponding to one or more of the homologous nucleic acid sequences. 2. The method of claim 1, wherein the plurality of oligonucleotide member types correspond to at least one additional region of heterogeneity. 3. The method of claim 1, wherein the alignment identifies a plurality of regions of heterogeniety and the set of oligonucleotides comprises a first plurality of oligonucleotides corresponding to a first of the regions of heterogeneity and a second plurality of oligonucleotides corresponding to a second of the regions of heterogeniety. 4. The method of claim 1, wherein the plurality of oligonucleotide member types are synthesized serially. 5. The method of claim 1, wherein the plurality of oligonucleotide member types are synthesized in parallel. 6. The method of claim 1, wherein the plurality of oligonucleotide member types are synthesized on an automatic synthesizer. 7. The method of claim 1, wherein the plurality of oligonucleotide member types are synthesized from tri-nucleotides. 8. The method of claim 1, wherein the plurality of oligonucleotide member types are partially synthesized by extension with a polymerase. 9. The method of claim 1, wherein the homologous nucleic acid sequences are aligned in a system comprising sequence alignment software. 10. The method of claim 1, wherein the homologous nucleic acid sequences are aligned by manual alignment. 11. The method of claim 1, further comprising recombining the oligonucleotide set. 12. The method of claim 11, wherein recombining the oligonucleotide set comprises hybridizing a set of overlapping family gene shuffling oligonucleotides and elongating the set of overlapping family gene shuffling oligonucleotides, thereby providing a population of recombined nucleic acids. 13. The method of claim 12, comprising recombining the population of recombined nucleic acids. 14. The method of claim 13, wherein recombining the population of recombined nucleic acids comprises hybridizing the population of recombined nucleic acids and extending the resulting hybridized recombined nucleic acids with a polymerase to form additionally recombined nucleic acids. 15. The method of claim 12, the method comprising: denaturing the population of recombined nucleic acids, thereby providing denatured recombined nucleic acids; reannealing the denatured recombined nucleic acids; extending the resulting reannealed recombined nucleic acids; and, optionally: selecting one or more of the resulting recombined nucleic acids for a desired property. 16. The method of claim 11, wherein recombining the oligonucleotide set comprises ligating one or more members of the set oligonucleotides, thereby producing at least one recombinant nucleic acid comprising subsequences from at least two of the plurality of parental nucleic acids. 17. The method of claim 16, wherein the ligation is performed with a ligase selected from the group consisting of: a DNA ligase, T4 DNA ligase, and a thermostable DNA ligase. 18. The method of claim 16, wherein the ligating is performed using the DNA repair system of a cell. 19. The method of claim 16, wherein the at least one recombinant nucleic acid encodes one or more fall-length protein. 20. The method of claim 16, wherein the at least one recombinant nucleic acid encodes a fragment of a full length protein, which fragment is recombined with one or more additional fragments to produce one or more full-length proteins. 21. The method of claim 11, wherein the oligonucleotides set is recombined to produce one or more phase-compatible recombinant nucleic acids. 22. The method of claim 21, wherein the phase compatible recombinant nucleic acids comprise one or more phase 1 intron. 23. The method of claim 11, wherein the oligonucleotides set comprises one or more module shuffling oligonucleotides. 24. The method of claim 11, wherein recombining the oligonucleotide set comprises extending members of the set oligonucleotides with a polymerase and ligating the resulting extended nucleic acids to produce a recombinant nucleic acid. 25. The method of claim 24, wherein the polymerase does not substantially displace or degrade downstream oligonucleotides which are hybridized to the template. 26. The method of claim 16, wherein the set of oligonucleotides are hybridized to a single-stranded template prior to ligation. 27. The method of claim 16, wherein the set of oligonucleotides are hybridized to a single-stranded template and extended with a polymerase prior to ligation. 28. The method of claim 27, wherein the single-stranded template comprises uracil. 29. The method of claim 27, wherein the single-stranded template is derived from a phage. 30. The method of claim 27, wherein the single-stranded template is produced in a dut- ung- strain of E. coli. 31. The method of claim 1, the set of oligonucleotides comprising at least 3 member types. 32. The method of claim 1, the set of oligonucleotides comprising at least 5 member types. 33. The method of claim 1, the set of oligonucleotides comprising at least 10 member types which correspond to one of the one or more regions of sequence heterogeneity. 34. The method of claim 1, the set of oligonucleotides comprising a plurality of homolgous oligonucleotide member types, wherein the homologous oligonucleotide member types are present in approximately equimolar amounts. 35. The method of claim 1, the set of oligonucleotides comprising a plurality of homolgous oligonucleotide member types, wherein the homologous oligonucleotide member types are present in non-equimolar amounts. 36. The method of claim 1, the set of oligonucleotides comprising a plurality of non-homolgous oligonucleotide member types. 37. The method of claim 1, wherein the set of oligonucleotides comprise one or more chimeraplast oligonucleotides. 38. The method of claim 37, wherein the chimeraplasts comprise codon-varied oligonucleotides. 39. The method of claim 1, wherein the set of oligonucleotides comprises a plurality of codon-varied oligonucleotides.

Details for Patent 6,426,224

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2019-01-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2019-01-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2019-01-19